Acenocoumarol is an anticoagulant drug used in the prevention of thromboembolic diseases in infarction and transient ischemic attacks, as well as management of deep vein thrombosis and myocardial infarction. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase.
- Mechanism
- Curator reviewed
Acenocoumarol inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent clotting factors, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited resulting in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.
- Primary indication
- For the treatment and prevention of thromboembolic diseases.Curator reviewed · 7 structured indications
- Formula / weight
- C19H15NO6 · 353.3255 g/mol (avg)
- First approval
- Canada, 2009
- Also known as
- Acenocoumarin · Acenocumarolo · Acenokumarin · Nicoumalone · Nicumalon
Resolves to
VABCILAOYCMVPS-UHFFFAOYSA-NSMILESCC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=OWhat you can answer from here — as of September 28, 2026
Which drugs share a target with Acenocoumarol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account